Get the Stockscreener App
3.62
2.95%
-0.11
After Hours:
3.69
0.07
+1.93%
Eledon Pharmaceuticals Inc stock is traded at $3.62, with a volume of 540.28K.
It is down -2.95% in the last 24 hours and up +32.12% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$3.73
Open:
$3.85
24h Volume:
540.28K
Relative Volume:
1.31
Market Cap:
$216.77M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-2.0223
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
-2.16%
1M Performance:
+32.12%
6M Performance:
-18.28%
1Y Performance:
+20.67%
1-Day Range:
$3.60
$3.85
1-Week Range:
$3.60
$3.95
52-Week Range:
$2.375
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.62 | 223.36M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Why is Eledon Pharmaceuticals Inc. stock attracting strong analyst attentionRapid portfolio appreciation - jammulinksnews.com
How many analysts rate Eledon Pharmaceuticals Inc. as a “Buy”High-profit capital plays - jammulinksnews.com
Published on: 2025-07-28 01:06:10 - jammulinksnews.com
What makes Eledon Pharmaceuticals Inc. stock price move sharplyDiscover stocks with explosive growth potential - jammulinksnews.com
Eledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated by Analysts at Craig Hallum - Defense World
Is Eledon Pharmaceuticals Inc. stock a good hedge against inflationHigh Confidence Trade Setups - Newser
Published on: 2025-07-27 20:41:15 - jammulinksnews.com
Eledon Pharmaceuticals Inc. Company Revenue and Profit Trends: A Deep DiveProfit Focused Trade Alerts - Newser
Eledon Pharmaceuticals (NASDAQ:ELDN) Coverage Initiated at Craig Hallum - Defense World
What drives Eledon Pharmaceuticals Inc. stock priceHigh-yield investments - PrintWeekIndia
Is Eledon Pharmaceuticals Inc. a good long term investmentConsistently high returns - PrintWeekIndia
Should I buy Eledon Pharmaceuticals Inc. stock before earningsFree Market Volatility Navigation Tips - jammulinksnews.com
Eledon Pharmaceuticals (ELDN) Receives Buy Rating from Craig-Hallum | ELDN Stock News - GuruFocus
What analysts say about Eledon Pharmaceuticals Inc. stockSkyrocketing returns - PrintWeekIndia
Can Eledon Pharmaceuticals Inc. stock recover from recent declineExponential wealth increase - jammulinksnews.com
Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart - TipRanks
Eledon Pharmaceuticals Inc. Stock Analysis and ForecastBreakout stock performance - jammulinksnews.com
How Eledon Pharmaceuticals Inc. stock performs during market volatilityDefensive Stock Picks with Upside - Newser
Midday Stock Roundup: loanDepot Shoots Up 16% - Orange County Business Journal
Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b - GlobeNewswire
Eledon to present updated kidney transplant study data at WTC By Investing.com - Investing.com Nigeria
Eledon to present updated kidney transplant study data at WTC - Investing.com India
New Phase 1b Data: Tegoprubart Shows Promise in Preventing Kidney Transplant Rejection30 Patient Update - Stock Titan
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):